Cellectar Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Cellectar Biosciences has a total shareholder equity of $8.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $16.0M and $7.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$13.91m |
| Equity | US$8.25m |
| Total liabilities | US$7.79m |
| Total assets | US$16.04m |
Recent financial health updates
Recent updates
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully
Aug 08
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Feb 12Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
Aug 23Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19
Aug 05Cellectar announces reverse stock split
Jul 21We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
May 10Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
Jan 20Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?
Oct 05We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely
May 20We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate
Nov 30
Financial Position Analysis
Short Term Liabilities: CLRB's short term assets ($14.9M) exceed its short term liabilities ($6.0M).
Long Term Liabilities: CLRB's short term assets ($14.9M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: CLRB is debt free.
Reducing Debt: CLRB had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLRB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CLRB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.6% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 15:02 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellectar Biosciences, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Keith Markey | Griffin Securities |
| Aydin Huseynov | Ladenburg Thalmann & Company |